171 related articles for article (PubMed ID: 38058065)
1. LncRNA
Jiang J; Dong W; Zhang W; Wang Q; Wang R; Wang J; Wu H; Dong H; Zhao RC; Wang J; Li Z
Discov Med; 2023 Dec; 35(179):995-1014. PubMed ID: 38058065
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of circular RNA septin 9 inhibits the malignant progression of breast cancer by reducing the expression of solute carrier family 1 member 5 in a microRNA-149-5p-dependent manner.
Wang J; Yang K; Cao J; Li L
Bioengineered; 2021 Dec; 12(2):10624-10637. PubMed ID: 34738502
[TBL] [Abstract][Full Text] [Related]
3. Circ_0000463 contributes to the progression and glutamine metabolism of non-small-cell lung cancer by targeting miR-924/SLC1A5 signaling.
Liu Y; Wang S; Pan S; Yan Q; Li Y; Zhao Y
J Clin Lab Anal; 2022 Jan; 36(1):e24116. PubMed ID: 34811815
[TBL] [Abstract][Full Text] [Related]
4. TEAD1 (TEA Domain Transcription Factor 1) Promotes Smooth Muscle Cell Proliferation Through Upregulating SLC1A5 (Solute Carrier Family 1 Member 5)-Mediated Glutamine Uptake.
Osman I; He X; Liu J; Dong K; Wen T; Zhang F; Yu L; Hu G; Xin H; Zhang W; Zhou J
Circ Res; 2019 Apr; 124(9):1309-1322. PubMed ID: 30801233
[TBL] [Abstract][Full Text] [Related]
5. Targeted Suppression and Knockout of ASCT2 or LAT1 in Epithelial and Mesenchymal Human Liver Cancer Cells Fail to Inhibit Growth.
Bothwell PJ; Kron CD; Wittke EF; Czerniak BN; Bode BP
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30029480
[TBL] [Abstract][Full Text] [Related]
6. Circ_0062558 promotes growth, migration, and glutamine metabolism in triple-negative breast cancer by targeting the miR-876-3p/SLC1A5 axis.
Yuan M; Zhang J; He Y; Yi G; Rong L; Zheng L; Zhan T; Zhou C
Arch Gynecol Obstet; 2022 Nov; 306(5):1643-1655. PubMed ID: 35284960
[TBL] [Abstract][Full Text] [Related]
7. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
[TBL] [Abstract][Full Text] [Related]
8. Circ_0001273 downregulation inhibits the growth, migration and glutamine metabolism of esophageal cancer cells via targeting the miR-622/SLC1A5 signaling axis.
Wu B; Chen Y; Chen Y; Xie X; Liang H; Peng F; Che W
Thorac Cancer; 2022 Jun; 13(12):1795-1805. PubMed ID: 35567340
[TBL] [Abstract][Full Text] [Related]
9. Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer.
Toda K; Nishikawa G; Iwamoto M; Itatani Y; Takahashi R; Sakai Y; Kawada K
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28749408
[TBL] [Abstract][Full Text] [Related]
10. Discoidin domain receptor 1 promotes hepatocellular carcinoma progression through modulation of SLC1A5 and the mTORC1 signaling pathway.
Pan Y; Han M; Zhang X; He Y; Yuan C; Xiong Y; Li X; Zeng C; Lu K; Zhu H; Lu X; Liu Q; Liang H; Liao Z; Ding Z; Zhang Z; Chen X; Zhang W; Zhang B
Cell Oncol (Dordr); 2022 Feb; 45(1):163-178. PubMed ID: 35089546
[TBL] [Abstract][Full Text] [Related]
11. ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.
Zhang Z; Liu R; Shuai Y; Huang Y; Jin R; Wang X; Luo J
Br J Cancer; 2020 Jan; 122(1):82-93. PubMed ID: 31819178
[TBL] [Abstract][Full Text] [Related]
12. Targeting ASCT2-mediated glutamine metabolism inhibits proliferation and promotes apoptosis of pancreatic cancer cells.
Wang W; Pan H; Ren F; Chen H; Ren P
Biosci Rep; 2022 Mar; 42(3):. PubMed ID: 35237783
[TBL] [Abstract][Full Text] [Related]
13. Deficiency in SLC25A15, a hypoxia-responsive gene, promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Zhang Q; Wei T; Jin W; Yan L; Shi L; Zhu S; Bai Y; Zeng Y; Yin Z; Yang J; Zhang W; Wu M; Zhang Y; Peng G; Roessler S; Liu L
J Hepatol; 2024 Feb; 80(2):293-308. PubMed ID: 38450598
[TBL] [Abstract][Full Text] [Related]
14. Circ_0000069 contributes to the growth, metastasis and glutamine metabolism in renal cell carcinoma (RCC) via regulating miR-125a-5p-dependent SLC1A5 expression.
Yang L; Wang L; Wu J; Wang Y
Transpl Immunol; 2023 Apr; 77():101764. PubMed ID: 36462557
[TBL] [Abstract][Full Text] [Related]
15. Targeting of the glutamine transporter SLC1A5 induces cellular senescence in clear cell renal cell carcinoma.
Kawakami I; Yoshino H; Fukumoto W; Tamai M; Okamura S; Osako Y; Sakaguchi T; Inoguchi S; Matsushita R; Yamada Y; Tatarano S; Nakagawa M; Enokida H
Biochem Biophys Res Commun; 2022 Jun; 611():99-106. PubMed ID: 35487063
[TBL] [Abstract][Full Text] [Related]
16. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
[TBL] [Abstract][Full Text] [Related]
17. ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine-addicted OSCC cells.
Luo Y; Li W; Ling Z; Hu Q; Fan Z; Cheng B; Tao X
Cancer Med; 2020 May; 9(10):3489-3499. PubMed ID: 32162845
[TBL] [Abstract][Full Text] [Related]
18. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.
Wang Q; Hardie RA; Hoy AJ; van Geldermalsen M; Gao D; Fazli L; Sadowski MC; Balaban S; Schreuder M; Nagarajah R; Wong JJ; Metierre C; Pinello N; Otte NJ; Lehman ML; Gleave M; Nelson CC; Bailey CG; Ritchie W; Rasko JE; Holst J
J Pathol; 2015 Jul; 236(3):278-89. PubMed ID: 25693838
[TBL] [Abstract][Full Text] [Related]
19. A Variant of SLC1A5 Is a Mitochondrial Glutamine Transporter for Metabolic Reprogramming in Cancer Cells.
Yoo HC; Park SJ; Nam M; Kang J; Kim K; Yeo JH; Kim JK; Heo Y; Lee HS; Lee MY; Lee CW; Kang JS; Kim YH; Lee J; Choi J; Hwang GS; Bang S; Han JM
Cell Metab; 2020 Feb; 31(2):267-283.e12. PubMed ID: 31866442
[TBL] [Abstract][Full Text] [Related]
20. Topotecan induces hepatocellular injury via ASCT2 mediated oxidative stress.
Zhou G; Qin M; Zhang X; Yang J; Yu H
Gastroenterol Hepatol; 2021 Jan; 44(1):1-12. PubMed ID: 33039171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
